cas 2306272-72-8|| where to buy 2-{4-[(benzyloxy)carbonyl]piperazin-1-yl}acetic acid hydrochloride

Produktname:2-{4-[(benzyloxy)carbonyl]piperazin-1-yl}acetic acid hydrochloride

IUPAC Name:2-{4-[(benzyloxy)carbonyl]piperazin-1-yl}acetic acid hydrochloride

: CAS：2306272-72-8; Molekulare Formel：C14H19ClN2O4; Reinheit：95%+

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM391044-500mg	in stock	ȁȬǊ
CM391044-1g	in stock	ŴȬŴ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2306272-72-8 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:2306272-72-8; Molekulare Formel:C14H19ClN2O4; Schmelzpunkt:-; SMILES-Code:Cl.OC(=O)CN1CCN(CC1)C(=O)OCC1=CC=CC=C1; Dichte:

: Katalognummer:CM391044; Molekulargewicht:314.77; Siedepunkt:; Mdl-Nr.:; Lagerung:

: Piperazines; Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.

: Lorundrostat; Mineralys Therapeutics announced that the first subject has been dosed in the Launch-HTN pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), when used as an add-on therapy to prescribed background treatment. Lorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled and resistant hypertension and CKD. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.